Abbott Launches SimpleScreen Blood Test for Colorectal Cancer Screening
Abbott Laboratories (ABT) has launched the FDA-approved blood test 'SimpleScreen CRC' in the United States to screen adults aged 45 and older at average risk of colorectal cancer. The new diagnostic tool, developed by Freenome, offers an additional non-invasive screening option for patients alongside Abbott’s existing Cologuard product. This expansion into more advanced blood-based diagnostics aligns with growing demand for convenient and accurate early detection methods in oncology care. By leveraging innovative technology from Freenome, Abbott aims to strengthen its position in the cancer screening market while improving patient access to reliable diagnostic solutions.
